Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and INCMGA00012 in Advanced Liposarcoma
NCT04438824Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2020
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retifanlimab and palbociclib in Liposarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Recommended Phase 2 Dose at 6 weeks and Best Overall Response Rate at 48 weeks. Started Jun 2020; status: active, not recruiting.
02
Drugs
retifanlimabpalbociclib
03
Conditions
Liposarcoma
Beyond the preview
Go deeper on NCT04438824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04438824.